🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

NeurologyICD-10: G70.0

Find Recruiting Clinical Trials for Myasthenia Gravis

Search AChR-positive, MuSK-positive, and generalized MG trials — complement inhibitors, FcRn inhibitors, and emerging therapies.

🔍 Search Myasthenia Gravis Trials →

About Myasthenia Gravis

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular junction disorder caused by antibodies targeting acetylcholine receptors (AChR, ~85% of patients), MuSK receptors (~10%), or LRP4. It is characterized by fluctuating muscle weakness and fatigability, typically affecting ocular (ptosis, diplopia), bulbar (dysphagia, dysarthria), and limb muscles, with potential respiratory involvement in crisis. Standard treatments include acetylcholinesterase inhibitors (pyridostigmine), immunosuppressants, thymectomy, and plasma exchange/IVIG for exacerbations. Several new biologic therapies have been recently approved, dramatically expanding the treatment landscape.

What Types of Myasthenia Gravis Clinical Trials Exist?

MG has one of the most rapidly expanding biologic pipelines in neurology. Complement inhibitors (eculizumab, ravulizumab, zilucoplan), FcRn inhibitors (efgartigimod, rozanolixizumab, nipocalimab) that reduce pathogenic IgG antibody levels, anti-CD20 agents (rituximab, inebilizumab), and CAR-T therapies are all in various stages of development. AChR antibody status (positive vs. negative/seronegative), disease generalization, current therapy, and MG Activities of Daily Living (MG-ADL) or Quantitative MG scores are standard eligibility variables.

Find Recruiting Myasthenia Gravis Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Myasthenia Gravis Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for myasthenia gravis?▾
Recruiting MG trials include FcRn inhibitors (efgartigimod extension studies, rozanolixizumab, nipocalimab), complement inhibitors, anti-CD20 combinations, CAR-T cell therapies targeting B cells or plasma cells, and biomarker studies. Both AChR-positive and MuSK-positive MG have active trial programs.
How does antibody status (AChR vs. MuSK) affect MG trial eligibility?▾
AChR antibody positivity vs. MuSK positivity vs. seronegative status significantly affects trial eligibility. Most trials enroll AChR-positive MG specifically. MuSK-positive MG has dedicated trial programs. Seronegative MG (negative for AChR and MuSK) has the fewest targeted trial options but may qualify for generalized MG trials using clinical criteria alone.
What MG severity scores are used in clinical trials?▾
Primary severity measures include MG-ADL (Myasthenia Gravis Activities of Daily Living, 0–24), QMG (Quantitative Myasthenia Gravis, 0–39), and MG Composite score. Most trials require a minimum MG-ADL score (typically ≥6) to confirm meaningful disease activity. MG Foundation of America (MGFA) classification (I–V) is also used. Know your most recent MG-ADL score if possible.

Related Conditions

Multiple SclerosisNeuromyelitis OpticaALS

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.